1.1Single aromatic carbocycle at A
The six-membered phenyl ring provides a rigid aromatic surface at A. The nitrile nitrogen at the meta position provides a hydrogen-bond acceptor outside the ring.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The six-membered phenyl ring provides a rigid aromatic surface at A. The nitrile nitrogen at the meta position provides a hydrogen-bond acceptor outside the ring.
The oxygen connects two methylene groups through carbon–oxygen single bonds. The bent ether geometry sets the local linker angle, and the oxygen supplies a hydrogen-bond acceptor.
The —P(=O)(OH)2 group forms a direct bond between phosphorus and a terminal linker carbon. Deprotonation of its acidic hydroxyl groups gives B a negative charge in water, with the charge state depending on pH.
Fluorine occupies the R1 position through a single bond and introduces zero additional carbon atoms. The polar bond withdraws electron density from the neighboring atoms through the inductive effect.
A single bond connects one carbon of the phenyl ring to the core at R3. The ring presents a planar aromatic surface, and rotation about the attachment bond changes the orientation of that surface relative to the core.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A tetrahydropyridoindole derivative with measured estrogen receptor activity serves as a reference control in a water monitoring bioassay. An aliquot of filtered water receives the derivative from a stock solution, and a second aliquot receives the same volume of stock solvent. Both aliquots are tested in cells carrying an estrogen response element upstream of a luciferase gene. The difference in luminescence records the response to the reference compound in the sample matrix.
An ether oxygen replaces the thioether sulfur in an A–S–CH₂–CH₂–B linker to give A–O–CH₂–CH₂–B. The tetrahydropyridoindole core and the attachment positions on A and B stay fixed across the two compounds. For an aromatic A bearing a hydroxy group at the linker site, alkylation with a two-carbon electrophile bearing B forms the ether linkage. A competitive binding assay measures the concentration of each compound that displaces half of a labeled estrogen tracer from the receptor.
A four-member compound series uses cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl as B, giving terminal rings of 3, 4, 5, and 6 carbon atoms. Each ring attaches through one ring carbon to the same methylene linker, and the core, A group, and remaining substituents stay fixed. The four compounds are tested at the same concentrations in a receptor binding assay. The resulting concentration-response curves show how binding varies with ring size.
Estrogen receptor-positive cells receive the same concentration of a tetrahydropyridoindole derivative for 30 minutes, 2 hours, or 8 hours. At the end of each exposure, the wells are rinsed twice and refilled with compound-free medium. Matched wells receive solvent alone or continuous compound exposure. Receptor-responsive transcript levels measured at washout and 4 and 24 hours later track how long the response persists.
A two-channel microfluidic device holds estrogen receptor-positive tumor spheroids in a hydrogel chamber beside a perfusion channel. The tetrahydropyridoindole derivative enters through the perfusion channel and diffuses through the hydrogel to the spheroids. A parallel device receives the same medium and solvent concentration. Effluent samples provide compound concentration measurements, and images collected over time record spheroid growth.
A liquid handler prepares an eight-point, threefold dilution series of each derivative in a 384-well plate with a constant final solvent concentration. It transfers each series into paired wells containing estrogen receptor reporter cells, with a fixed estradiol concentration in one well of each pair. A plate reader measures luciferase output, and software fits concentration-response curves for both assay conditions. Parallel viability measurements flag concentrations at which loss of viable cells can account for reduced reporter output.
The —C≡C— unit connects the attachment sites along a linear axis. The triple bond fixes the spacer geometry while single bonds at its ends permit rotation of the attached groups.
A is quinolin-6-yl, a ten-membered bicyclic aromatic group with one ring nitrogen. The group attaches through carbon 6 of the benzene portion, and the pyridine nitrogen serves as a hydrogen-bond acceptor.
R2 is —CH2OH, attached through the methylene carbon. The terminal hydroxyl group can donate and accept hydrogen bonds.
One R4 group is morpholin-4-yl, a saturated six-membered ring with one oxygen and one nitrogen. The ring attaches through nitrogen and places the ether oxygen across the ring from the attachment point.
Ra in —N(Ra)— is isopropyl, a branched three-carbon aliphatic group. Its central carbon bonds directly to the linker nitrogen and carries two methyl groups.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring. The ring can be five, six, seven or eight-membered.B · US 7,750,042 B2 · ¶ 57
Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group.A · US 7,037,940 B2 · abstract
In aspect, Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group.B · US 7,750,042 B2 · ¶ 24
Examples of suitable linkage groups include a ketone (—C(O)—), alkene, alkyne, phenylene, ether (—O—), thioether (—S—), or amine [—N(Ra)]—, wherein Ra is defined below.A · US 7,037,940 B2 · ¶ 49
Examples of suitable linkage groups include a ketone (—C(O)—), alkene, alkyne, phenylene, ether (—O—), thioether (—S—), or amine [—N(Ra)]—, wherein Ra is defined below.B · US 7,750,042 B2 · ¶ 51
In a fourth example of a compound represented by Structural Formula (IV), R1 and R2 are both a substituted or unsubstituted aliphatic group, preferably both a substituted or unsubstituted lower alkyl group, including a C3-C8 cycloalkyl group substituted with at least one lower alkyl group (e.g., methyl, ethyl, n-propyl, n-butyl, n-pentyl, cyclopropyl, 1-methylcyclopropyl, 2-methylcyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).B · US 7,750,042 B2 · ¶ 38
R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbB · US 7,750,042 B2 · abstract
Examples of suitable substituents include —OH, halogen (—Br, —Cl, —I and —F), —ORa, —O—CORa, —CORa, —CN, —NO2, —COOH, —SO3H, —NH2, —NHRa, —N(RaRb), —COORa, —CHO, —CONH2, —CONHRa, —CON(RaRb), —NHCORa, —NRCORa, —NHCONH2, —NHCONRaH, —NHCON(RaRb), —NRcCONH2, —NRcCONRaH, —NRcCON(RaRb), —C(═NH)—NH2, —C(═NH)—NHRa, —C(═NH)—N(RaRb), —C(═NRc)—NH2, —C(═NRc)—NHRa, —C(═NRc)—N(RaRb), —NH—C(═NH)—NH2, —NH—C(═NH)—NHRa, —NH—C(═NH)—N(RaRb), —NH—C(═NRc)—NH2, —NH—C(═NRc)—NHRa, —NH—C(═NRc)—N(RaRb)A · US 7,037,940 B2 · ¶ 57
R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbB · US 7,750,042 B2 · abstract
Examples of suitable substituents include —OH, halogen (—Br, —Cl, —I and —F), —ORa, —O—CORa, —CORa, —CN, —NO2, —COOH, —SO3H, —NH2, —NHRa, —N(RaRb), —COORa, —CHO, —CONH2, —CONHRa, —CON(RaRb), —NHCORa, —NRCORa, —NHCONH2, —NHCONRaH, —NHCON(RaRb), —NRcCONH2, —NRcCONRaH, —NRcCON(RaRb), —C(═NH)—NH2, —C(═NH)—NHRa, —C(═NH)—N(RaRb), —C(═NRc)—NH2, —C(═NRc)—NHRa, —C(═NRc)—N(RaRb), —NH—C(═NH)—NH2, —NH—C(═NH)—NHRa, —NH—C(═NH)—N(RaRb), —NH—C(═NRc)—NH2, —NH—C(═NRc)—NHRa, —NH—C(═NRc)—N(RaRb)A · US 7,037,940 B2 · ¶ 57
Examples of suitable substituents include —OH, halogen (—Br, —Cl, —I and —F), —ORa, —O—CORa, —CORa, —CN, —NO2, —COOH, —SO3H, —NH2, —NHRa, —N(RaRb), —COORa, —CHO, —CONH2, —CONHRa, —CON(RaRb), —NHCORa, —NRCORa, —NHCONH2, —NHCONRaH, —NHCON(RaRb), —NRcCONH2, —NRcCONRaH, —NRcCON(RaRb), —C(═NH)—NH2, —C(═NH)—NHRa, —C(═NH)—N(RaRb), —C(═NRc)—NH2, —C(═NRc)—NHRa, —C(═NRc)—N(RaRb), —NH—C(═NH)—NH2, —NH—C(═NH)—NHRa, —NH—C(═NH)—N(RaRb), —NH—C(═NRc)—NH2, —NH—C(═NRc)—NHRa, —NH—C(═NRc)—N(RaRb)B · US 7,750,042 B2 · ¶ 59
Ra–Rd are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group, preferably an alkyl, benzylic or aryl group.A · US 7,037,940 B2 · ¶ 57
Ra-Rd are each independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group, preferably an alkyl, benzylic or aryl group.B · US 7,750,042 B2 · ¶ 59
An empty cell means only that no passage was reproduced there.
Therefore, there is an urgent need for agents which can enhance the desirable tumor attacking properties of anti-cancer agents without further increasing their undesirable side-effects.A · US 7,037,940 B2 · ¶ 3
It has now been found that certain bis[thio-hydrazide amide] compounds significantly enhance the anti-cancer activity of taxol.A · US 7,037,940 B2 · ¶ 4
Therefore, there is an urgent need for agents which can enhance the desirable tumor attacking properties of anti-cancer agents without further increasing their undesirable side-effects.B · US 7,750,042 B2 · ¶ 3
It has now been found that certain bis[thio-hydrazide amide] compounds significantly enhance the anti-cancer activity of paclitaxel.B · US 7,750,042 B2 · ¶ 4
patent.fyi, US 2026/0355165 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355165/, SHA-256 d241697551d8c820ff8a7de31a4bd0758b80ab57819ee0879d50c991409a18c1